GMAB — Genmab A/S

Is GMAB overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of August 19, 2026

Genmab A/S (GMAB) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $34.11. The rating moved from Neutral to Overbought on August 7, 2026.

See all overbought Healthcare stocks →

AI analysis

Genmab combines a deep antibody-engineering platform with partnered commercialization streams and a pipeline that could deliver several near- to mid-term value inflection points; balance sheet support and strategic collaborations reduce immediate dilution risk. Key upside catalysts include clinical readouts, regulatory progress, and partnership milestone recognition, while principal downside scenarios include clinical failures, partner execution issues, and sector-wide sentiment reversals.

Key factors

  • Diversified pipeline in antibody-based therapeutics with multiple mid-to-late stage assets that offer near- and medium-term value inflection opportunities
  • Established collaboration and commercialization partnerships that provide non-dilutive revenue and milestone/royalty streams
  • Strong scientific and platform capabilities in antibody engineering that support differentiated product candidates and potential premium pricing
  • Favorable sector tailwinds for biologics and advanced biologic modalities, increasing investor interest and potential for higher M&A multiples
  • Conservative balance-sheet posture relative to pure clinical-stage peers (cash / partnership receipts reduce near-term financing risk)
  • Market sentiment steady; limited macro noise in the immediate trading window supports focused stock moves around company-specific catalysts

Risks

  • Clinical or regulatory setbacks for lead assets that could materially compress valuation
  • Concentration risk if major revenue streams are tied to a small number of partnered products or milestones
  • Commercial execution and competitive dynamics in key therapeutic areas could erode pricing or market share
  • Dependence on partners for development, regulatory filings, and commercialization may slow value capture or create timing uncertainty
  • Biotech funding and sentiment volatility; sector rotation away from growth could depress share multiples
  • Currency, reimbursement, or payer-pricing pressures in major markets that reduce realized revenue or royalty rates

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for GMAB — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.